RNS Number : 7859F
31 October 2018
31 October 2018
("Concepta" or the "Company")
myLotus® launch: Saturday 3rd November The Fertility Show, Olympia, London
Concepta Plc (AIM: CPT), the innovative UK healthcare company and developer of the proprietary self-test platform ("myLotus® ") and suite of emerging test products targeting the mobile health market is pleased to announce the launch of its breakthrough myLotus® product for women's fertility at the Fertility Show, Olympia, London, stand H22 over the weekend of the 3rd/4th November 2018.
myLotus® will be available to women who are planning to start a family or for those who have previously struggled to naturally conceive, enabling couples an alternative prior to considering more costly IVF treatment.
The Fertility Show stand will also include representation from Key Opinion Leaders, fertility doctors and health experts who will be available to discuss myLotus®.
Matthew Walls, Chairman said: "The Fertility Show marks the UK launch of our myLotus® fertility product and the start of our roll-out across CE territories. Women attending the show can exclusively buy a Starter Pack, consisting of a myLotus® monitor, 3 packs of 20 Ovulation Tests (LH) and 3 packs of 3 Pregnancy Tests (hCG), at the 'Special Launch' price of £199. We look forward to an exciting Fertility Show and to welcoming women and couples to our stand. myLotus® will also be available online at www.myLotus.com"
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
+44 (0) 20 7399 9400
Yellow Jersey PR Limited (Financial PR)
Georgia Colkin / Joe Burgess/Katie Bairsto
Tel: +44 (0) 776 932 5254
About Concepta Plc:
Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on increasing a woman's chances of getting pregnant naturally and for unexplained infertility in women.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and is preparing its B2C launch in the UK and Europe. The Company has identified a significant global market opportunity with revenue potential of the EU and Chinese unexplained infertility market estimated to be worth c.£600m per annum.
Concepta has also made progress in establishing relationships with a number of distributors in China where myLotus® has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the B2C route in the near future.
myLotus® is expected to be beneficial to users diagnosed with 'unexplained infertility' who have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF typically not offered until two years. Research indicates couples start to take positive action ahead of this time with little medical support to help them do so.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.